Endocrinology

New findings reveal semaglutide significantly enhances walking ability and quality of life for patients with T2D and PAD.

A new study reveals hybrid closed-loop technology significantly improves glucose control for pregnant women with T1D.

Automated insulin delivery systems enhance blood glucose control for pregnant women with type 1 diabetes, potentially advancing diabetes care.

Semaglutide 7.2 mg shows promising results, achieving a mean 21% weight loss in obesity treatment.

The ACHIEVE-1 trial reveals orforglipron's potential as a breakthrough treatment for type 2 diabetes.

New research reveals amycretin's promising potential for weight loss in obesity treatment, advancing to phase 3 trials for effective management options.

Most participants (83%) did not require exogenous insulin 1 year after zimislecel (VX-880) infusion.

From barriers to implementing evidence-based care to innovations in combination therapy, here are 5 key updates from the annual meeting.

An overview of 7 presentations included as late-breaking clinical trials at ADA 2025.

The recent Lancet Commission on Obesity has repositioned the former risk factor as a disease, indicating and emphasizing a variety of complications.

By targeting insulin resistance at its source, dual receptor agonists may have a more efficient method of tackling the growing obesity problem, as well as its cardiovascular effects.

In this special episode, cohosts preview the most anticipated data and explore clinical implications in diabetes and obesity.

Budoff suggests monitoring serum lipoproteins like Lp(a) and ApoB to predict cardiovascular disease risk in patients with no conventional indicators.

Martin reviews recent trends in cardiovascular disease and contributing underlying risk factors, describing them as a “call to action” for cardiovascular care.

Lopez discusses the evolving understanding of the utility of SGLT2 inhibitors and GLP-1 RAs in heart failure care, including both HFpEF and HFrEF.

Incretin-based therapies for obesity and diabetes may be capable of treating a much wider range of diseases, including Alzheimer’s and Parkinson’s.

Califf discusses the difficulty patients face in accessing healthcare information despite rapid technology and treatment advancements.

Lopez reviews findings from an analysis of ARISE-HF highlighting racial and ethnic differences in baseline characteristics and diabetic cardiomyopathy disease progression.

The pooled analysis of BROOKLYN and BROADWAY data outline obicetrapib’s impact on HbA1c reduction and a trend toward lower new-onset diabetes risk.

Michos discusses framing obesity as hyperandrogenism, with reductions in estrogen production contributing to higher visceral adiposity.

Pagidipati describes barriers to implementing guideline-directed medical therapy in patients with cardiometabolic diseases and steps needed to overcome them.

Hosts break down data from the CONFIDENCE trial on the safety and efficacy of finerenone plus empagliflozin in patients with T2D and CKD.

Semaglutide’s reduction in systolic blood pressure could indicate more potential for cardiovascular protection than simply its well-known glycemic benefits.

New research has indicated that glucagon-like peptide-1 receptor agonists result in lower all-cause mortality and risk of cardiovascular events in patients with concurrent sleep apnea and type 2 diabetes.

Hosts discuss a consensus repot from the ADA focused on screening and early interview of MASLD in people with diabetes.